FDG-PET in thyroid cancer

被引:15
|
作者
Crippa, F [1 ]
Alessi, A [1 ]
Gerali, A [1 ]
Bombardieri, E [1 ]
机构
[1] Natl Canc Inst, PET Ctr, Div Nucl Med, I-20133 Milan, Italy
来源
TUMORI JOURNAL | 2003年 / 89卷 / 05期
关键词
differentiated thyroid cancer (DTC); FDG-PET; medullary thyroid cancer (MTC); thyroid cancer scintigraphy;
D O I
10.1177/030089160308900517
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The most widely used diagnostic nuclear medicine technique in well-differentiated thyroid cancer (DTC) is radioiodine scintigraphy, either diagnostic or post-therapeutic, together with serum thyroglobulin (Tg) measurement; this combination is usually able to determine the presence or absence of cancer. FDG-PET has shown less sensitivity in DTC that retains the ability to trap I-131. Several alternative procedures with single photon emitting radiopharmaceuticals have been evaluated including whole body scan with Tl-201, Tc-99m-sestamibi or tetrofosmin scan, with different sensitivity and specificity. The main advantage of these tests is that their results are not influenced by the levels of TSH, therefore they do not require a hypothyroid state in the patient. Recently positron emission tomography (PET) with FDG has been demonstrated to be highly useful in thyroid cancer patients with a negative I-131 whole body scan but measurable Tg. According to reports in the literature FDG-PET in the follow-up of operated patients has a sensitivity ranging from 70% to 90% in identifying the source of Tg. The demonstration of lesions can lead to a change in treatment including surgery or external radiation instead of radioiodine treatment. In Europe, medullary thyroid cancer (MTC) is currently visualized by Tc-99m pentavalent dimercaptosuccinic acid (DMSA) and 99mTc-sestamibi or tetrofosmin. Metaiodobenzylguanidine (MIBG) radiolabeled with I-123 or I-131 is another reliable radiopharmaceutical for medullary tumors. In-111-pentetreotide scan is positive in a high percentage of patients because MTC expresses somatostatin receptors. FDG-PET has an interesting role to play in calcitonin-positive patients, where PET has been shown to correctly identify lesions in cervical and mediastinal lymph nodes as well as at distant sites. Furthermore, calcitonin-guided PET has been found to be superior to CT and MRI in many patients. Recent reports indicated that F-18-DOPA scan in MTC seems to be more accurate than FDG-PET.
引用
收藏
页码:540 / 543
页数:4
相关论文
共 50 条
  • [41] Accumulation of glucose in keloids with FDG-PET
    Toshiyuki Ozawa
    Terue Okamura
    Teruichi Harada
    Michinari Muraoka
    Nozomi Ozawa
    Koichi Koyama
    Yuichi Inoue
    Masamitsu Ishii
    Annals of Nuclear Medicine, 2006, 20 : 41 - 44
  • [42] Predictive and prognostic value of FDG-PET
    de Geus-Oei, Lioe-Fee
    Oyen, Wim J. G.
    CANCER IMAGING, 2008, 8 (01): : 70 - 80
  • [43] Achilles tendonitis detected by FDG-PET
    Huang, SS
    Yu, JQ
    Chamroonrat, W
    Alavi, A
    Zhuang, HM
    CLINICAL NUCLEAR MEDICINE, 2006, 31 (03) : 147 - 148
  • [44] FDG-PET for germ cell tumors
    de Wit, M.
    Kotzerke, J.
    ONKOLOGE, 2008, 14 (06): : 581 - +
  • [45] Relationship between glucose transporter, hexokinase and FDG-PET in esophageal cancer
    Tohma, T
    Okazumi, S
    Makino, H
    Cho, A
    Mochiduki, R
    Shuto, K
    Kudo, H
    Matsubara, K
    Gunji, H
    Ochiai, T
    HEPATO-GASTROENTEROLOGY, 2005, 52 (62) : 486 - 490
  • [46] FDG-PET for axillary lymph node staging in primary breast cancer
    Crippa, F
    Gerali, A
    Alessi, A
    Agresti, R
    Bombardieri, E
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2004, 31 (Suppl 1) : S97 - S102
  • [47] Diffuse and diffuse-plus-focal uptake in the thyroid gland identified by using FDG-PET: prevalence of thyroid cancer and Hashimoto's thyroiditis
    Seiji Kurata
    Masatoshi Ishibashi
    Yuji Hiromatsu
    Hayato Kaida
    Ikuyo Miyake
    Masafumi Uchida
    Naofumi Hayabuchi
    Annals of Nuclear Medicine, 2007, 21 : 325 - 330
  • [48] Chronic cholecystitis detected by FDG-PET
    Yu, XQ
    Kung, JW
    Potenta, S
    Xiu, Y
    Alavi, A
    Zhuang, HM
    CLINICAL NUCLEAR MEDICINE, 2004, 29 (08) : 496 - 497
  • [49] Accumulation of glucose in keloids with FDG-PET
    Ozawa, T
    Okamura, T
    Harada, T
    Muraoka, M
    Ozawa, N
    Koyama, K
    Inoue, Y
    Ishii, M
    ANNALS OF NUCLEAR MEDICINE, 2006, 20 (01) : 41 - 44
  • [50] FDG-PET after radiotherapy is a good prognostic indicator of rectal cancer
    Oku, S
    Nakagawa, K
    Momose, T
    Kumakura, Y
    Abe, A
    Watanabe, T
    Ohtomo, K
    ANNALS OF NUCLEAR MEDICINE, 2002, 16 (06) : 409 - 416